Skip to main content

Diuretics in Heart Failure

A Critical Appraisal of Efficacy and Tolerability

Drugs volume 69, pages 2451–2461 (2009)Cite this article

Abstract

Heart failure is a significant cause of morbidity and mortality worldwide. While the aetiology varies and there are a wide variety of treatment options, a large amount of the morbidity related to heart failure is due to fluid retention and the symptoms of volume overload. Multiple neurohormonal pathways are activated in heart failure, and contribute to the symptoms of fluid retention and volume overload. Although not ideal, diuretic therapy is one of the mainstays of treatment of fluid overload in patients with heart failure. This review focuses on the pathophysiology of heart failure leading to volume overload, the different classes of diuretics used in alleviating the symptoms of fluid retention, their mechanisms of action within the kidney, and strategies for using them in ways that minimize their deleterious effects in patients with heart failure.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. American Heart Association. Heart failure [online]. Available from URL: http://www.americanheart.org/presenter.jhtml?identifier=1486 [Accessed 2009 Sep 11]

  2. Sica D. Sodium and water retention in heart failure and diuretic therapy: basic mechanisms. Cleve Clin J Med 2006; 73 Suppl. 2: S2–7; discussion S30-3

    PubMed  Article  Google Scholar 

  3. Francis G, Benedict C, Johnstone D, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724–9

    PubMed  Article  CAS  Google Scholar 

  4. Francis G. Acute decompensated heart failure: the cardiorenal syndrome. Cleve Clin J Med 2006; 73 Suppl. 2: S8–13; discussion S30-3

    PubMed  Article  Google Scholar 

  5. Schrier R, Abraham W. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341(8): 77–85

    Google Scholar 

  6. Johnson RJ. Essential medical physiology. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1998

    Google Scholar 

  7. Brunton L. Goodman & Gillman’s pharmacology. 11th ed. New York: McGraw-Hill, 2006

    Google Scholar 

  8. Tan L, Jalil J, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991; 69(5): 1185–93

    PubMed  Article  CAS  Google Scholar 

  9. Thohan V, Torre-Amione G, Koerner M. Aldosterone antagonism and congestive heart failure: a new look at and old therapy. Curr Opin Cardiol 2004; 19(4): 301–8

    PubMed  Article  Google Scholar 

  10. Weber K, Grilla C. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83(6): 1849–63

    PubMed  Article  CAS  Google Scholar 

  11. Konstam M, Rousseau M, Kronenberg M, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992; 86(2): 431–8

    PubMed  Article  CAS  Google Scholar 

  12. Pitt B, Zannad F, Remme W, et al. The effect of spironolactone on mobidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341(10): 709–17

    PubMed  Article  CAS  Google Scholar 

  13. Konstam M, Kronenberg M, Rousseau M, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with asymptomatic systolic dysfunction. Circulation 1993; 88(5): 2277–83

    PubMed  Article  CAS  Google Scholar 

  14. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 51730–6

    Article  Google Scholar 

  15. Libby P, Bonow RO, Mann DL, et al., editors. Braunwald’s heart disease: a textbook of cardiovascular medicine. Vol. 1. 8th ed. Philadelphia (PA): Saunders/Elsevier, 2008: 621

    Google Scholar 

  16. Brater C. Diuretic therapy. New Engl J Med 1998; 339: 387–95

    PubMed  Article  CAS  Google Scholar 

  17. Wang D, Gotlieb S. Diuretics: still the mainstay of treatment. Crit Care Med 2008; 36 (1 Suppl.): S89–94

    PubMed  Article  CAS  Google Scholar 

  18. Lahav M, Regev A, Ra’anani P, et al. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest 1992; 102: 725–31

    PubMed  Article  CAS  Google Scholar 

  19. Howard P, Dunn M. Effectiveness of continuous infusions of loop diuretics for severe heart failure. J Cardiovasc Med 2006; 7: 5–10

    Article  Google Scholar 

  20. Dormans T, Van Meyel J, Gerlag P, et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection verses continuous infusion. J Am Coll Cardiol 1996; 28: 376–82

    PubMed  Article  CAS  Google Scholar 

  21. Rudy D, Voelker J, Greene P, et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Int Med 1991; 115: 360–6

    PubMed  CAS  Google Scholar 

  22. Vargo D, Kramer W, Black P, et al. Bioavailability, pharmacokinetic, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmocol Ther 1995; 57: 601–9

    Article  CAS  Google Scholar 

  23. Uchida T, Yamanaga K, Nishikawa M, et al. Anti-aldosteronergic effect of torasemide. Euro J Pharm 1991; 205: 145–50

    Article  CAS  Google Scholar 

  24. Tsutamoto T, Sakai H, Wada A, et al. Torasemide inibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2004; 44: 2252–3

    PubMed  Article  CAS  Google Scholar 

  25. Lopez B, Querejeta R, Gonzalez A, et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43: 2028–35

    PubMed  Article  CAS  Google Scholar 

  26. Cosin J, Diez J. Torasemide on chronic heart failure: results of the TORC study. Eur J Heart Fail 2002; 4: 507–13

    PubMed  Article  CAS  Google Scholar 

  27. Murray M, Deer M, Furgusion J, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111: 513–20

    PubMed  Article  CAS  Google Scholar 

  28. Peacock W, Costanzo M, DeMarco T, et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE Registry. Cardiology 2009; 113: 12–9

    PubMed  Article  Google Scholar 

  29. Francis G, Siegel R, Goldsmith S, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann Int Med 1985; 103(1): 1–6

    PubMed  CAS  Google Scholar 

  30. McCurley J, Hanlon S, Wei S, et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004; 44: 1301–7

    PubMed  Article  CAS  Google Scholar 

  31. Juurlink D, Mamdani M, Lee D, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004; 351: 543–51

    PubMed  Article  CAS  Google Scholar 

  32. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 384(14): 1309–21

    Article  Google Scholar 

  33. Kramer B, Schweda F, Riegger G. Diuretic treatment and diuretic resistance in heart failure. Am J Med 1999; 106: 90–6

    PubMed  Article  CAS  Google Scholar 

  34. Ellison D. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001; 96: 132–43

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgements

Neither Anita D. Szady nor James A. Hill have received any type of funding for the preparation of this paper. Neither Dr Szady nor Dr Hill have any conflicts of interest with regards to authorship of this paper and are the sole authors of the article.

Author information

Affiliations

  1. Division of Cardiovascular Medicine, The University of Florida, Box 100277, Gainesville, Florida, 32610-0277, USA

    Anita D. Szady & James A. Hill

Authors
  1. Anita D. Szady
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James A. Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anita D. Szady.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Szady, A.D., Hill, J.A. Diuretics in Heart Failure. Drugs 69, 2451–2461 (2009). https://doi.org/10.2165/11319920-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11319920-000000000-00000

Keywords

  • Furosemide
  • Heart Failure Patient
  • Volume Overload
  • Loop Diuretic
  • Thiazide Diuretic